Related protocols CJC-1295 DAC (2 mg Vial) Long-acting GHRH analog for sustained growth hormone release
In people with T2D and overweight/obesity, 16 weeks of danuglipron led to a placebo-adjusted WL up to 4.2 kg with the highest dose of 120 mg twice daily
Results vary, and the product is not a treatment for pigmentation, ageing or any dermatological condition
Nevertheless, the putative effects of the combined GLP-1 analog and bupropion/naltrexone treatment on weight loss are undefined
Cellular protection: Preserves healthy cell function and reduces oxidative damage
Lunetta KL, D'Agostino RB, Karasik D, Benjamin EJ, Guo CY, Govindaraju R, Kiel DP, Kelly-Hayes M, Massaro JM, Pencina MJ, Seshadri S, Murabito JM: Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study